The Future of Value-Based Care and Payment Models in Cancer Care


Brenton Fargnoli, MD: I think, undoubtedly, that there’s a multi-stakeholder movement [toward] value in oncology—whether that’s providers, payers, or even life science companies, increasingly. And it’s just so important that as we measure the success of these programs, whether it’s measuring the success of the Oncology Care Model or Part B, or these other things, that we keep in mind that the ultimate success metric is the value delivered to that patient.

So, including them in these discussions, including them in every conversation around, “Is value being delivered?” is going to be critically important—that we don’t stray toward too much policy or [show] too much favoritism toward one stakeholder. Because, at the end of the day, the patient is at the center of this alternative payment model shift.

Rena M. Conti, PhD: I would say the following: in this rush to focus on value-based care, we lose sight of the fact that we are a very rich country that believes, strongly, in providing access to medical care for our entire population. We can afford both—to provide basic access to cancer screening and, at the same time, provide access to the most expensive, cutting-edge, precision medicine that can provide durable cures—if we spend our money wisely.

So, what I hope to see, and I think is beginning to be part of a national conversation, is a focus on how we can get this system focused on value—where we’re using money most wisely and we’re not putting patients at the center of really expensive stuff that doesn’t do that much for them or at the center of stuff that does a lot for them but they have to foot the bill “too much.” So, hopefully, we’re moving in that direction.

Andrew L. Pecora, MD, CPE: I’d like to end by saying it’s very easy to get angry and cynical about all of this, but at the end of the day, somebody has to really start to think about this. It’s wonderful that you 2 have dedicated part of your careers [to] thinking about this. And, for me, I really believe that no one has the right to do the wrong thing for a patient. We can argue about what the right thing is, and that’s always going to be an argument in medicine. But no one has the right to do the wrong thing. The better we can identify the wrong things and prevent them from happening, I think there’s plenty of money from that savings that could be used for all the things you just said.

The key, over the next few years, is to make certain that we don’t create perverse incentives or cross-incentives or we don’t have 2 parts of government actually working against each other. It’s going to take people from the economics community, from the information technology community, and from the medical community to work in partnership to make this a reality.

On behalf of our panel, we thank you for following the Fall 2016 program of the Oncology Stakeholder Summit Series. We hope you found this Peer Exchange® informative and hope you will join us as the series continues.

Related Videos
Nicolas Ferreyros, Community Oncology Alliance
Vikki Walton, MBA, Mercer
Matthew Crowley, MD, MHS, associate professor of medicine, Duke University School of Medicine.
Dr Seun Ross: Achieving Equity is Necessary to Sustain the Health Care System
Jennifer Sturgill, DO, Central Ohio Primary Care
Donna Fitzsimons
Nick Ferreyros, Community Oncology Alliance
Ryan Haumschild, PharmD, MS, MBA, director of pharmacy, Emory Winship Cancer Institute
Kristine Slam, MD, FACP, Central Ohio Surgical Associates
Related Content
© 2023 MJH Life Sciences
All rights reserved.